JP2024527539A5 - - Google Patents
Info
- Publication number
- JP2024527539A5 JP2024527539A5 JP2023580404A JP2023580404A JP2024527539A5 JP 2024527539 A5 JP2024527539 A5 JP 2024527539A5 JP 2023580404 A JP2023580404 A JP 2023580404A JP 2023580404 A JP2023580404 A JP 2023580404A JP 2024527539 A5 JP2024527539 A5 JP 2024527539A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune effector
- sequence shown
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110749536 | 2021-07-01 | ||
| CN202110749536.3 | 2021-07-01 | ||
| PCT/CN2022/103037 WO2023274380A1 (zh) | 2021-07-01 | 2022-06-30 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527539A JP2024527539A (ja) | 2024-07-25 |
| JP2024527539A5 true JP2024527539A5 (cg-RX-API-DMAC7.html) | 2025-07-07 |
Family
ID=84690444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580404A Pending JP2024527539A (ja) | 2021-07-01 | 2022-06-30 | ＩＬ１３Ｒα２を標的としたユニバーサルＣＡＲ－Ｔ細胞及びその製造方法と使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240376216A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4364746A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527539A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768445A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023274380A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025025597A1 (zh) * | 2023-08-03 | 2025-02-06 | 森妙生物科技(西安)有限公司 | 一种抗体或其抗原结合片段及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| KR101763499B1 (ko) | 2012-11-07 | 2017-07-31 | 화이자 인코포레이티드 | 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체 |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| ES2928296T3 (es) * | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
| CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| EP3765041A4 (en) * | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| JP7748935B2 (ja) | 2019-08-27 | 2025-10-03 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ |
-
2022
- 2022-06-30 WO PCT/CN2022/103037 patent/WO2023274380A1/zh not_active Ceased
- 2022-06-30 JP JP2023580404A patent/JP2024527539A/ja active Pending
- 2022-06-30 EP EP22832192.3A patent/EP4364746A4/en active Pending
- 2022-06-30 US US18/575,628 patent/US20240376216A1/en active Pending
- 2022-06-30 CN CN202280004526.XA patent/CN115768445A/zh active Pending